Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Name: Verified Rigor Record — Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Item: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Rating: 100
Author: Αlpha¹

Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L.

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.6.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This paper on a phase 2 RCT of sacituzumab tirumotecan vs docetaxel in EGFR-mutated NSCLC demonstrates rigorous methodology across most dimensions: strong scientific premise, sound study design with randomisation and BIRC, adequate reporting of biological variables, ethical approvals, and key resources. Two dimensions—data/code availability and reporting transparency—have fixable gaps: code is in supplementary files rather than a citable repository, the CONSORT checklist is missing, and one conclusion slightly overstates the evidence.

Synthesized findings from three independent reviewer models and a copyedit pass. The statistics verification component recomputed 8 reported tests and found 2 minor p-value discrepancies that do not alter conclusions. One reference was flagged as not found in the registry and should be verified. The claim audit identified one overstated conclusion. Dimensions scored as 'not applicable' in checklists were excluded from the score calculation.

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

overstatedWhat this study addsReviewers 1, 3
These findings for sac-TMT may redefine treatment standards for this population.
While the results are promising, the claim of 'redefining treatment standards' is strong for a Phase 2 trial, especially given the ongoing Phase 3 trials mentioned as necessary for validation.
Evidence: This study provides evidence supporting sac-TMT as an effective treatment for these patients with disease progression after treatment with EGFR-tyrosine kinase inhibitors and platinum based chemotherapy. Based on the promising results of the current, OptiTROP-Lung03, trial, the China National Medical Products Administration has recently approved the use of sac-TMT, establishing it as the first trophoblast cell surface antigen 2 directed antibody-drug conjugate approved for the treatment of lung cancer in the world. To further validate the findings, several phase 3 randomised controlled trials are ongoing.
“These findings for sac-TMT may redefine treatment standards for this population”
supportedAbstract, ConclusionsReviewer 1
Sac-TMT showed statistically significant and clinically meaningful improvements in objective response rate, progression-free survival, and overall survival compared with docetaxel, with a manageable safety profile in patients with EGFR-mutated locally advanced or metastatic NSCLC.
The paper presents statistical evidence for significant improvements in ORR, PFS, and OS, and detailed safety data supporting a manageable profile.
Evidence: BIRC assessed objective response rate was significantly higher in the sac-TMT group (45% (41/91)) v docetaxel (16% (7/45)), with a difference of 29% (95% confidence interval (CI) 15% to 43%; one sided P<0.001). Median progression-free survival was longer with sac-TMT than with docetaxel assessed by BIRC (6.9 v 2.8 months; hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001). The 12 month overall survival rate was 73% with sac-TMT and 54% with docetaxel (hazard ratio 0.49, 0.27 to 0.88; one sided P=0.007). Grade ≥3 treatment related adverse events were less frequent with sac-TMT than with docetaxel (56% v 72%), with no new safety signals identified.
“Sac-TMT showed statistically significant and clinically meaningful improvements in objective response rate, progression-free survival, and overall survival compared with docetaxel, with a manageable safety profile in patients with EGFR -mutated locally advanced or metastatic NSCLC.”
supportedWhat this study addsReviewer 1
The novel trophoblast cell surface antigen 2 directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) showed higher response rates, longer progression-free survival, and improved overall survival with manageable toxicity for patients with pre-treated advanced EGFR-mutated NSCLC compared with docetaxel.
The results section provides direct statistical comparisons for response rates, PFS, OS, and toxicity profiles, supporting this claim.
Evidence: BIRC assessed objective response rate was 45% (41/91; 95% CI 35% to 56%) in the sac-TMT group and 16% (7/45; 95% CI 7% to 30%) in the docetaxel group, with a difference of 29% (95% CI 15% to 43%; one sided P<0.001). BIRC assessed median progression-free survival was 6.9 months (95% CI 5.4 to 8.2) in the sac-TMT group compared with 2.8 months (1.6 to 4.1) in the docetaxel group. The sac-TMT group showed a significant 70% reduction in risk of disease progression or death (hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001). The 12 month overall survival rate was 73% (95% CI 62% to 81%) in the sac-TMT group and 54% (39% to 67%) in the docetaxel group (hazard ratio 0.49, 0.27 to 0.88; one sided P=0.007). Grade ≥3 treatment related adverse events occurred in 51 out of 91 patients (56%) in the sac-TMT group and 33 out of 46 patients (72%) in the docetaxel group.
“The novel trophoblast cell surface antigen 2 directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) showed higher response rates, longer progression-free survival, and improved overall survival with manageable toxicity for patients with pre-treated advanced EGFR -mutated NSCLC compared with docetaxel”
supportedConclusionsReviewer 1
The China National Medical Products Administration has recently approved the use of sac-TMT, establishing it as the first trophoblast cell surface antigen 2 directed antibody-drug conjugate approved for the treatment of lung cancer in the world.
This is a factual statement about regulatory approval, which is presented as a direct outcome of the trial's promising results.
Evidence: Based on the promising results of the current, OptiTROP-Lung03, trial, the China National Medical Products Administration has recently approved the use of sac-TMT, establishing it as the first trophoblast cell surface antigen 2 directed antibody-drug conjugate approved for the treatment of lung cancer in the world.
“Based on the promising results of the current, OptiTROP-Lung03, trial, the China National Medical Products Administration has recently approved the use of sac-TMT, establishing it as the first trophoblast cell surface antigen 2 directed antibody-drug conjugate approved for the treatment of lung cancer in the world.”
supportedAbstract, ResultsReviewer 2
Sac-TMT showed a statistically significant higher BIRC-assessed objective response rate compared with docetaxel.
The claim is directly supported by the primary endpoint analysis, which shows a 45% vs 16% ORR with a reported p-value <0.001 and a 95% CI for the difference that excludes zero.
Evidence: Table 2 and the Results section report the ORR data and the statistical comparison.
“BIRC assessed objective response rate was significantly higher in the sac-TMT group (45% (41/91)) v docetaxel (16% (7/45)), with a difference of 29% (95% confidence interval (CI) 15% to 43%; one sided P<0.001).”
supportedAbstract, ResultsReviewer 2
Sac-TMT showed statistically significant and clinically meaningful improvements in progression-free survival compared with docetaxel.
The claim is supported by the PFS analysis showing a median of 6.9 vs 2.8 months, HR 0.30, with a p-value <0.001 and a 95% CI for the HR that excludes 1.0.
Evidence: Results section and Figure 4 report the PFS data and analysis.
“Median progression-free survival was longer with sac-TMT than with docetaxel assessed by BIRC (6.9 v 2.8 months; hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001)”
supportedAbstract, ResultsReviewer 2
Sac-TMT showed statistically significant and clinically meaningful improvements in overall survival compared with docetaxel.
The claim is supported by the OS analysis showing a 51% reduction in risk of death (HR 0.49, p=0.007), which met the pre-specified boundary for significance. The sensitivity analyses adjusting for crossover further support this.
Evidence: Results section and Figure 4 report the OS data and analysis.
“The 12 month overall survival rate was 73% with sac-TMT and 54% with docetaxel (hazard ratio 0.49, 0.27 to 0.88; one sided P=0.007).”
supportedAbstract, ResultsReviewer 2
Sac-TMT has a manageable safety profile compared with docetaxel.
The claim is supported by the safety data showing lower rates of Grade ≥3 treatment-related adverse events (56% vs 72%), lower rates of febrile neutropenia (0% vs 20%), and no new safety signals.
Evidence: Results, 'Safety' section and Table 3 report the adverse event data.
“Grade ≥3 treatment related adverse events were less frequent with sac-TMT than with docetaxel (56% v 72%), with no new safety signals identified.”
supportedDiscussionReviewer 2
Sac-TMT is a promising treatment option for patients with pre-treated, EGFR-mutated, locally advanced or metastatic NSCLC.
This conclusion is supported by the statistically significant and clinically meaningful improvements in ORR, PFS, and OS with a manageable safety profile, as demonstrated in the study.
Evidence: The entire Results section supports this conclusion.
“Taken together, these findings suggest that sac-TMT is a promising treatment option combining meaningful clinical efficacy with a manageable safety profile for patients with pre-treated, EGFR-mutated, locally advanced or metastatic NSCLC.”
supportedAbstractReviewer 3
Sac-TMT showed statistically significant and clinically meaningful improvements in objective response rate, progression-free survival, and overall survival compared with docetaxel.
The paper presents all three endpoint results with p-values and confidence intervals, meeting statistical significance. Improvements (45% vs 16% ORR, HR 0.30 for PFS, HR 0.49 for OS) are large and clinically meaningful.
Evidence: Results section: ORR difference 29% (95% CI 15–43%; p<0.001); PFS HR 0.30 (0.20–0.46; p<0.001); OS HR 0.49 (0.27–0.88; p=0.007).
“Sac-TMT showed statistically significant and clinically meaningful improvements in objective response rate, progression-free survival, and overall survival compared with docetaxel”
supportedResults, EfficacyReviewer 3
Sac-TMT reduces the risk of death by 51% compared with docetaxel.
The OS hazard ratio is 0.49, representing a 51% risk reduction, with a p-value of 0.007 (one-sided), which reached the pre-specified interim boundary.
Evidence: Results: HR 0.49, 95% CI 0.27–0.88, one-sided p=0.007.
“the sac-TMT group showed a 51% reduction in risk of death (hazard ratio 0.49, 0.27 to 0.88; one sided P=0.007)”
supportedResults, SafetyReviewer 3
Sac-TMT has a manageable safety profile.
Safety data are presented, showing grade ≥3 treatment-related adverse events were less frequent with sac-TMT than docetaxel (56% vs 72%), with no new safety signals. Common AEs are managed with supportive care.
Evidence: Safety section: grade ≥3 events 56% vs 72%; no febrile neutropenia in sac-TMT group; stomatitis managed with dose modification.
“No new safety signals identified”

Recomputed 8 tests: 6 consistent, 2 inconsistent, 8 via agent-written checks.

Rigor

Eight Dimensions8 pass

12 major claims1 overstated11 supported

7 copyedit issues flagged: mostly consistency, clarity.

Checked 30 references: 29 verified — 1 unresolved.

Reproducibility

5 data/code links checked; 5 live.

dataMendeley DataLIVEHTTP 200
https://data.mendeley.com/datasets/hts8z9mx4w/1
Resolves to Mendeley Data (data repository).
datahttps://clinicaltrials.gov/ct2/show/NCT05631262LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT05870319LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT06074588LIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT06305754LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

Ready after moderate edits. The paper is methodologically sound but requires fixing the data/code availability (deposit code in a version-controlled repository), adding a CONSORT checklist reference, tempering one over-claim in the discussion, verifying the unresolved reference, correcting the copyedit placeholders, and providing full antibody identification before submission.

1.
HIGHreporting
Explicitly state adherence to the CONSORT 2010 statement for randomised trials and submit a completed CONSORT checklist as a supplementary file.
This is required by most journals for RCTs and verifies that all key reporting elements are covered.
2.
HIGHdata code
Deposit the analysis code in a version-controlled public repository (e.g., GitHub, Zenodo) with a persistent DOI instead of only as supplementary files.
Supplementary files are not version-controlled or citable; a repository ensures long-term accessibility and reproducibility.
3.
HIGHreporting
Temper the claim 'These findings for sac-TMT may redefine treatment standards for this population' in the Discussion to reflect that this is a Phase 2 trial and validation from ongoing Phase 3 trials is needed.
Overstating conclusions from a Phase 2 trial is a common reason for reviewer pushback and may mislead readers.
4.
HIGHother
Verify and correct the reference flagged as 'not found in the registry' (Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA for EGFR-mutant NSCLC Accepted by NMPA, DOI: 10.1016/s0140-6736(21) – the DOI appears truncated).
A reference that cannot be located in any registry may be fabricated or have a broken DOI, which is an integrity concern.
5.
HIGHrigor
Provide complete identification for the TROP2 monoclonal antibody (EPR20043) in the Methods section: include vendor, catalog number, RRID, and dilution used for immunohistochemistry.
Clone alone is insufficient for unambiguous identification; RRIDs are the community standard for antibody reporting.
6.
MEDIUMstatistics
Add a statement verifying the proportional hazards assumption for the Cox models (or note that the log-rank test used is robust to non-proportionality).
Explicit verification of model assumptions strengthens the statistical analysis and pre-empts reviewer questions.
7.
MEDIUMcopyedit
Remove or replace all empty parentheses '()' and '(, , )' in the Results section (Patients and Efficacy subsections) with the correct figure/table references.
Empty parentheses are placeholders that break the manuscript flow and indicate incomplete final formatting.
8.
MEDIUMcopyedit
In the Results, Efficacy subsection, specify which figure shows the best change from baseline in target lesion size at the start of the sentence, and replace the empty parentheses with correct references.
Missing figure references confuse the reader and indicate incomplete final formatting.
9.
MEDIUMcopyedit
Rephrase 'The study team did not perform or have access to efficacy analysis or summary during the trial' to 'The study team did not perform or have access to any interim efficacy analyses or summaries during the trial' for clarity.
Clarifies that interim analyses, not final analyses, are referenced, aligning with standard trial conduct.
10.
MEDIUMreporting
In the Methods or a note to Table 2, clarify the data cut-off dates: the primary analysis cut-off (6 June 2024) versus the final PFS/OS analysis cut-off (31 Dec 2024) to avoid ambiguity.
Consistency between table footnotes and text regarding data cut-off dates prevents confusion about which analysis is reported.
11.
MEDIUMreporting
Report race/ethnicity demographics explicitly (e.g., 'all patients were of Chinese ancestry') in the baseline table or Methods.
Race/ethnicity is a key generalizability factor; implicit reporting is insufficient for transparency.
12.
MEDIUMreporting
Consider reporting the exact p-value for the primary endpoint as a two-sided value or clearly state that one-sided testing was pre-specified and justified in the protocol.
One-sided p-values can be ambiguous; explicit justification reduces reviewer concern about significance inflation.
13.
LOWother
Add a brief statement on how outliers in safety or efficacy data were handled (e.g., 'no outliers were excluded from the analyses').
Addresses the missing outlier handling sub-criterion and pre-empts reviewer questions about data exclusions.

Full text (52,350 chars)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →

Sacituzumab tirumotecan versus docetaxel for previously treated &lt;i&gt;EGFR&lt;/i&gt;-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial